BenevolentAI is a company that is revolutionizing the pharmaceutical industry by using artificial intelligence (AI) to discover and develop new drugs. The company was founded in 2013 by Ken Mulvany, a former investment banker, and has since grown to become a leading player in the field of AI-driven drug discovery.
The traditional drug discovery process is a long and expensive one, taking up to 15 years and costing billions of dollars. It involves a lot of trial and error, with researchers testing thousands of compounds to find one that is effective against a particular disease.